NADAC acquisition cost data for BELSOMRA 5 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00006000510 | $12.79 | 2022-01-06 | Rx |
| 00006000530 | $12.79 | 2022-01-06 | Rx |
| 00006000510 | $12.79 | 2022-01-06 | Rx |
| 00006000530 | $12.79 | 2022-01-06 | Rx |
| 00006000510 | $12.79 | 2022-01-06 | Rx |
| 00006000530 | $12.79 | 2022-01-06 | Rx |
| 00006000510 | $12.79 | 2022-01-06 | Rx |
| 00006000530 | $12.79 | 2022-01-06 | Rx |
| 00006000510 | $12.79 | 2022-01-06 | Rx |
| 00006000530 | $12.79 | 2022-01-06 | Rx |
Generic: Suvorexant | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $94.3M | 243,885 | 60,252 | $11.99 |
| 2020 | $104.1M | 253,504 | 61,153 | $12.59 |
| 2021 | $114.7M | 262,719 | 63,614 | $13.37 |
| 2022 | $130.0M | 280,812 | 70,601 | $14.17 |
| 2023 | $161.2M | 329,090 | 86,387 | $14.98 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $16.7M | 33,487 | 9,116 |
| Texas | $14.8M | 29,713 | 8,256 |
| Florida | $10.8M | 21,412 | 5,995 |
| North Carolina | $8.9M | 18,279 | 4,770 |
| New York | $7.1M | 15,792 | 4,361 |
| Georgia | $6.7M | 13,208 | 3,666 |
| Indiana | $5.7M | 11,648 | 3,003 |
| Missouri | $5.4M | 11,432 | 2,677 |
| Illinois | $5.0M | 10,071 | 2,613 |
| Ohio | $4.4M | 9,599 | 2,381 |
| Tennessee | $4.4M | 9,073 | 2,346 |
| Alabama | $4.2M | 8,654 | 2,203 |
| Pennsylvania | $4.0M | 8,274 | 2,179 |
| Arizona | $3.7M | 6,823 | 2,094 |
| Wisconsin | $3.5M | 7,147 | 1,717 |
| South Carolina | $3.4M | 6,946 | 2,050 |
| Louisiana | $3.4M | 6,847 | 2,011 |
| Colorado | $3.3M | 6,258 | 1,794 |
| Oklahoma | $3.3M | 6,982 | 1,738 |
| New Jersey | $3.3M | 6,375 | 1,685 |
| Arkansas | $2.9M | 6,111 | 1,630 |
| Virginia | $2.6M | 5,148 | 1,483 |
| Minnesota | $2.6M | 5,105 | 1,248 |
| Michigan | $2.5M | 5,153 | 1,371 |
| Connecticut | $2.5M | 5,154 | 1,305 |
| Washington | $2.4M | 4,900 | 1,356 |
| Massachusetts | $2.4M | 5,092 | 1,353 |
| Kentucky | $1.9M | 4,026 | 1,120 |
| Iowa | $1.8M | 3,919 | 851 |
| Kansas | $1.7M | 3,681 | 911 |
| Maryland | $1.7M | 3,161 | 928 |
| Utah | $1.4M | 2,980 | 706 |
| Nebraska | $1.4M | 2,872 | 645 |
| Idaho | $1.2M | 2,669 | 622 |
| Nevada | $1.1M | 2,219 | 736 |
| Mississippi | $1.1M | 2,157 | 634 |
| West Virginia | $989.0K | 2,115 | 555 |
| Oregon | $900.0K | 1,823 | 534 |
| New Mexico | $856.7K | 1,663 | 456 |
| Maine | $631.5K | 1,295 | 324 |
| Montana | $595.6K | 1,290 | 307 |
| New Hampshire | $552.5K | 1,194 | 337 |
| Puerto Rico | $538.2K | 1,237 | 253 |
| Alaska | $523.5K | 963 | 273 |
| South Dakota | $456.4K | 990 | 219 |
| Delaware | $443.4K | 800 | 271 |
| Wyoming | $351.7K | 714 | 189 |
| Rhode Island | $336.2K | 780 | 190 |
| Hawaii | $265.9K | 525 | 157 |
| North Dakota | $237.1K | 468 | 161 |
| Vermont | $190.4K | 396 | 131 |
| District of Columbia | $158.7K | 287 | 94 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.